Charles River Laboratories International, Inc. and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, announced a high-quality (HQ) plasmid DNA development and manufacturing agreement.
NUS Medicine will utilize Charles River’s market-leading contract development and manufacturing organization (CDMO) expertise in HQ and GMP-compliant plasmid DNA, which serves as a critical starting material for its engineered stem cell cancer therapy and builds on a historic provision of research-grade plasmid.
Phase-Appropriate Plasmid Solutions
NUS Medicine will leverage this collaboration to access Charles River’s center of excellence and established manufacturing platform, eXpDNA™.
In recent years, Charles River has significantly expanded its cell and gene therapy portfolio to streamline complex supply chains and meet the growing demand for plasmid DNA, viral vector, and cell therapy services. Combined with the Company’s legacy testing capabilities, Charles River offers an industry-leading “concept to cure” advanced therapeutic solution.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!